Status:
COMPLETED
Preoperative Aspirin and Postoperative Antiplatelets in Coronary Artery Bypass Grafting: The PAPA CABG Study
Lead Sponsor:
Hamilton Health Sciences Corporation
Collaborating Sponsors:
Bristol-Myers Squibb
Conditions:
Coronary Artery Disease
Coronary Artery Bypass Grafting
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
Main Research Question(s): What is the effect of continuing aspirin until the time of coronary artery bypass graft surgery and of adding clopidogrel to aspirin after coronary artery bypass graft surg...
Detailed Description
BACKGROUND: Platelets play a central role in the pathogenesis of ischemic complications (coronary artery bypass graft occlusion, myocardial infarction, stroke) following CABG surgery. Aspirin and clop...
Eligibility Criteria
Inclusion
- Patients 18 years of age or older
- Undergoing on-pump, elective coronary artery bypass grafting with at least 2 free grafts
- Patient able to give informed consent
Exclusion
- planned date of surgery is \<5 days from planned recruitment date
- patient has clear indication for anticoagulation (eg. mechanical heart valve, atrial fibrillation) or ADP receptor antagonist (eg. drug-eluting stent)
- allergy to or intolerance of aspirin or clopidogrel
- history of bleeding diathesis, significant GI bleed, ICH, or liver failure
- Patient has known renal failure or contraindication for Cardiac CT Angio
- Patient has had previous cardiac surgery
Key Trial Info
Start Date :
July 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2008
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT00330772
Start Date
July 1 2006
End Date
December 1 2008
Last Update
August 3 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hamilton General Hospital
Hamilton, Ontario, Canada, L8L 2X2